Research programme: phosphodiesterase IV inhibitors - Novartis

Drug Profile

Research programme: phosphodiesterase IV inhibitors - Novartis

Alternative Names: ABE-171; NVP-ABE-171

Latest Information Update: 14 Jul 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Novartis
  • Class Benzoic acids; Naphthyridines; Oxadiazoles
  • Mechanism of Action Type 4 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Preclinical Asthma; Chronic obstructive pulmonary disease

Most Recent Events

  • 14 Jul 2010 Preclinical development is ongoing in United Kingdom
  • 24 Apr 2007 Preclinical development is still ongoing
  • 22 Sep 2003 This programme is still in active development
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top